Lilly(Eli) & Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Did you know?
Profit margin of 31.7% — that's well above average.
Current Price
$955.19
+0.20%GoodMoat Value
$1015.63
6.3% undervaluedProfile
Valuation (TTM)
Market Cap$903.02B
P/E43.75
EV$896.05B
P/B34.03
Shares Out945.38M
P/Sales13.85
Revenue$65.18B
EV/EBITDA33.84
Lilly(Eli) & Company (LLY) Stock Analysis
GoodMoat Analysis
Eli Lilly is a high-quality pharmaceutical company with a potentially durable competitive moat, driven by its blockbuster drugs and innovation pipeline. However, its current valuation appears to be pricing in near-perfect execution, leaving a marginal margin of safety for a value investor.
Read full analysis
Eli Lilly is a leading pharmaceutical company whose business is anchored by blockbuster drugs like Mounjaro and Zepbound for diabetes and obesity, driving exceptional recent financial performance. Applying the GoodMoat framework, the company demonstrates a strong moat, likely scoring high on criteria like Proprietary Data (clinical trial data and patents), Regulatory Barriers (FDA approvals), and Technology Leadership in GLP-1 agonists. Its quality indicators are robust, with an operating margin of 40.4%, ROE of 77.8%, and revenue growth of 42.6% YoY, all pointing to a high-quality, profitable business. According to the Decision Framework, this passes the Moat & Quality Gate for further analysis. The valuation assessment, however, introduces caution. The current P/E of 42x is elevated, and the GoodMoat Target of $1,015.63 implies a margin of safety of only about 11.6% from the current price of $909.98, which falls into the 'Marginal' (10-20%) band. While the business itself is strong, the price demands flawless future growth and faces risks like eventual patent expirations. For a value investor, this presents a scenario that is 'with caution'—the company is worth investigating further for its quality, but the valuation does not offer a compelling margin of safety at present.
Market Cap$903.02B
Current Price$955.19
P/E Ratio43.75
Forward P/E—
PEG Ratio0.86
EPS$22.95
Book Value$28.07
P/B Ratio34.03
LLY Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 15.4% FCF growth (CAGR)
Cash vs Debt
Net Debt: 35.2B
Revenue
22.3B
FY19
24.5B
FY20
28.3B
FY21
28.5B
FY22
34.1B
FY23
45.0B
FY24
65.2B
FY25
Net Income
8.3B
FY19
6.2B
FY20
5.6B
FY21
6.2B
FY22
5.2B
FY23
10.6B
FY24
20.6B
FY25
LLY 52-Week Range
$622.37
$1108.10
50-Day MA: $987.18200-Day MA: $899.14
Did you know?
Price sits at 69% of its 52-week range.
Lilly(Eli) & Company (LLY) Financial Summary
Lilly(Eli) & Company (LLY) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. The stock currently trades at $955.19 with a market capitalization of $903.02B.
Key valuation metrics include a P/E ratio of 43.75, price-to-book ratio of 34.03, and EPS of $22.95. The company reports a profit margin of 31.7% and return on equity of 77.8%.
LLY Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $903.02B |
| P/E Ratio | 43.75 |
| EPS | $22.95 |
| P/B Ratio | 34.03 |
| P/S Ratio | 13.85 |
| EV/EBITDA | 33.84 |
| Dividend Yield | 0.60% |
| Profit Margin | 31.7% |
| Return on Equity | 77.8% |
| Debt/Equity | 1.60 |
LLY Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $22.32B | $8.32B |
| FY20 | $24.54B | $6.19B |
| FY21 | $28.32B | $5.58B |
| FY22 | $28.54B | $6.24B |
| FY23 | $34.12B | $5.24B |
| FY24 | $45.04B | $10.59B |
| FY25 | $65.18B | $20.64B |
Lilly(Eli) & Company (LLY) Valuation
Based on GoodMoat's DCF model, Lilly(Eli) & Company has a fair value estimate of $1015.63. At the current price of $955.19, the stock appears 6.0% undervalued relative to our intrinsic value estimate.
LLY Quality Indicators
Lilly(Eli) & Company maintains a profit margin of 31.7% and an operating margin of 40.4%. Return on equity stands at 77.8%. The current ratio is 1.58. Debt-to-equity ratio is 1.60.
About Lilly(Eli) & Company
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
LLY Free Cash Flow
Lilly(Eli) & Company generated $8.97B in trailing twelve-month free cash flow, representing an FCF yield of 0.99%. This low FCF yield may reflect heavy reinvestment or growth spending.
LLY Shares Outstanding
Lilly(Eli) & Company has 0.95 billion shares outstanding at a share price of $955.19, giving it a market capitalization of $903.02B.
LLY Recent Insider Trades
Recent insider transactions at Lilly(Eli) & Company include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| LILLY ENDOWMENT INC | SELL | 895 | $971171.66 |
| LILLY ENDOWMENT INC | SELL | 1,390 | $1.51M |
| LILLY ENDOWMENT INC | SELL | 3,593 | $3.90M |